Rheumatology (Oxford, England) · 2025
Association of validated patient reported outcome measures with patients' self-reported disease status in axial spondyloarthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Redeker Imke, Tsiami Styliani, Klavdianou Kalliopi, Oezdemir Yaren Elif, Sewerin Philipp, Kiefer David, Andreica Ioana, Kernder Anna, Vossen Diana, Kiltz Uta, Baraliakos Xenofon
Аннотация
OBJECTIVE: In axSpA, validated PROs are well-established in clinical trials, but it remains unclear whether they comprehensively reflect patients' discomfort and disease status. We aimed to investigate how patients' self-reported disease status compares with validated clinical trial measures during routine clinical visits.
METHODS: Data from axSpA patients' initial and last five visits were retrospectively analysed. ASDAS, BASDAI, ASAS20, ASAS40 and ASAS partial remission were assessed at each visit and compared with patients' self-reported disease status, categorized into very good (status satisfaction), mild, severe and very severe based on patients' self-reported opinion on the level of severity of symptom burden related to axSpA. The association of these PROs with patients' self-reported disease status was analysed using mixed models.
RESULTS: A total of 3,120 visits over a median follow-up of 4.7 years from 557 axSpA patients were analyzed. Very good or mild self-reported disease status was reported in 98.7% of visits with inactive and 90.9% of visits with low ASDAS compared to 67.9% with high and 39.3% with very high ASDAS. Severe or very severe self-reported disease status was reported in 15.1% of visits with ASAS20 achievement, in 7.2% with ASAS40 achievement, and in 0.6% with achievement of ASAS partial remission, compared with 26.0% without ASAS20 achievement, 25.1% without ASAS40 achievement, and 30.1% without achievement of ASAS partial remission.
CONCLUSIONS: Patients' self-reported disease status was well captured by ASDAS and BASDAI in most clinical visits. Other investigated measures used in clinical trials failed to capture patients' self-reported disease status in a large proportion of visits.
METHODS: Data from axSpA patients' initial and last five visits were retrospectively analysed. ASDAS, BASDAI, ASAS20, ASAS40 and ASAS partial remission were assessed at each visit and compared with patients' self-reported disease status, categorized into very good (status satisfaction), mild, severe and very severe based on patients' self-reported opinion on the level of severity of symptom burden related to axSpA. The association of these PROs with patients' self-reported disease status was analysed using mixed models.
RESULTS: A total of 3,120 visits over a median follow-up of 4.7 years from 557 axSpA patients were analyzed. Very good or mild self-reported disease status was reported in 98.7% of visits with inactive and 90.9% of visits with low ASDAS compared to 67.9% with high and 39.3% with very high ASDAS. Severe or very severe self-reported disease status was reported in 15.1% of visits with ASAS20 achievement, in 7.2% with ASAS40 achievement, and in 0.6% with achievement of ASAS partial remission, compared with 26.0% without ASAS20 achievement, 25.1% without ASAS40 achievement, and 30.1% without achievement of ASAS partial remission.
CONCLUSIONS: Patients' self-reported disease status was well captured by ASDAS and BASDAI in most clinical visits. Other investigated measures used in clinical trials failed to capture patients' self-reported disease status in a large proportion of visits.